S-1/A: Lakewood-Amedex Biotherapeutics Files for Nasdaq Direct Listing

Lakewood-Amedex Biotherapeutics Inc. is pursuing a direct listing on the Nasdaq Capital Market and a $7.5 million Series C Preferred Stock financing to advance its antimicrobial pipeline, despite ongoing significant losses and a going concern warning.

Summary

• Lakewood-Amedex Biotherapeutics Inc. is seeking a direct listing on the Nasdaq Capital Market under the symbol LABT, which is contingent on SEC and Nasdaq approval and the completion of a Series C Preferred Shares financing.
• The company has secured agreements for a private placement of 937,500 shares of Series C Preferred Stock for gross proceeds of $7.5 million, with an original issue discount of 20%.
• The Series C Preferred Stock will be convertible into common stock at the lower of $10.00 per share or 80% of the 5-day average closing price, with a floor price of $1.00, potentially leading to a maximum of 9,375,000 common shares.
• The lead product candidate, Nu-3, a broad-spectrum Bisphosphocin antimicrobial, is being developed for the topical treatment of mildly infected diabetic foot ulcers (iDFU) and is planned to enter a Phase 2a safety and dose-response study.
• The company's Bisphosphocin class of compounds is designed with a novel mechanism of action to destabilize bacterial membranes, potentially reducing resistance development, and has shown broad-spectrum activity against resistant strains like MRSA in non-clinical studies.
• Lakewood-Amedex holds 68 issued and 36 pending patent applications for its products and technologies, with protection extending through at least 2038 and potentially 2044 for recent applications.
• The company reported a net loss of $3.8 million for the year ended December 31, 2025, an improvement from a $4.8 million net loss in 2024.
• Research and development expenses decreased by approximately $0.8 million to $1.3 million in 2025, primarily due to workforce reductions and reclassification of salary expenses.
• General and administrative expenses increased by approximately $0.6 million to $2.5 million in 2025, driven by higher stock-based compensation and legal/audit fees for the direct listing.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern due to recurring losses and a significant working capital deficit of approximately $2.1 million as of December 31, 2025.
• A 1-for-5.92 reverse stock split was effected on September 29, 2025, to meet Nasdaq's minimum per-share price requirement.
• RBW Capital Partners LLC is acting as financial advisor for the direct listing and placement agent for the Series C private placement, and will receive 272,219 advisory shares (1.75% of fully diluted shares) and a 7.0% placement fee from the private placement gross proceeds.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While the company has a promising novel drug class and secured significant financing, the ongoing substantial losses and explicit going concern warning indicate high financial risk. The direct listing process itself also introduces additional market volatility risks.

Positives

• Successfully completed first exploratory human clinical trials for lead product Nu-3, showing positive antimicrobial response and improved wound healing trends in iDFU patients.
• The Bisphosphocin class of antimicrobials has a novel mechanism of action designed to enable rapid elimination of a broad spectrum of bacteria, including resistant pathogens and biofilms, with a low likelihood of resistance emergence in in vitro experiments.
• The company holds a robust intellectual property portfolio with 68 issued and 36 pending patents, providing protection through at least 2038 and potentially 2044.
• Nu-3 gel formulation is designed for direct administration to the site of infection, allowing high local concentrations with minimal systemic exposure, potentially reducing side effects.
• Preclinical data for Nu-3 demonstrated effectiveness in murine skin infection models against MRSA, with the gel outperforming the solution formulation.
• A porcine toxicology study established a high no adverse effect level (NOAEL) for Nu-3 gel, supporting higher concentrations for up to two weeks of treatment in clinical settings.
• The company has successfully discussed and aligned a Phase 2b clinical program for Nu-3 in iDFU with the FDA, and plans to precede it with a smaller Phase 2a study to establish early proof of concept and dose response.
• Net loss decreased from $4.8 million in 2024 to $3.8 million in 2025, and net cash used in operating activities decreased from $5.7 million in 2024 to $1.9 million in 2025.
• Secured $7.5 million in gross proceeds from a Series C Preferred Stock financing, expected to fund operations for at least 12 months post-listing and complete the Phase 2a study.

Negatives

• The company has a limited operating history and has not generated any revenue from product sales since inception.
• Incurred significant net losses since inception, with an accumulated deficit of $53.4 million as of December 31, 2025.
• The independent registered public accounting firm expressed substantial doubt about the company's ability to continue as a going concern.
• The direct listing process is novel and differs from a traditional underwritten IPO, potentially leading to greater volatility in stock price and uncertain trading volume.
• The company has identified material weaknesses in its internal controls over financial reporting, including limited documentation, segregation of duties, and management review controls.
• The financial advisor, RBW Capital Partners LLC, has a potential conflict of interest due to its dual role as financial advisor for the direct listing and placement agent for the private placement, and its receipt of advisory shares.
• The Series C Preferred Stock includes conversion price reset provisions, which may cause significant dilution to common stockholders if the stock price falls below the fixed conversion price.
• A significant number of shares (4,689,177) are being registered for resale, with 3,770,669 immediately available, which could create an oversupply and depress the stock price.

Risks

• The successful development of biopharmaceutical products is highly uncertain, and current product candidates have not been approved for commercial sale, potentially leading to substantial delays or inability to complete development and commercialization.
• Regulatory approval processes (FDA, EMA) are lengthy, time-consuming, and unpredictable; preclinical or early clinical trial outcomes may not predict success in later trials, and results may not meet regulatory requirements.
• Product candidates may cause adverse events, toxicities, or undesirable side effects, hindering regulatory approval, market acceptance, or commercial potential.
• Even if approved, product candidates may not achieve adequate market acceptance among physicians, patients, and payors, and market size estimates may be smaller than anticipated.
• Significant competition exists from companies with greater financial, manufacturing, marketing, and R&D resources, potentially leading to superior, safer, or more cost-effective products.
• Reliance on third parties for preclinical studies, clinical trials, and manufacturing poses risks of delays, non-compliance, or failure to meet deadlines.
• Complexities in manufacturing and supply, or changes in methods, could increase costs or delay clinical trials and commercial availability.
• Relationships with healthcare professionals and third-party payors are subject to healthcare fraud and abuse laws, potentially leading to criminal sanctions, civil penalties, and financial losses.
• Misconduct or regulatory noncompliance by employees or third parties could adversely affect the business.
• Limited resources may be allocated to less profitable or less successful product candidates or indications.
• Developing product candidates in combination with other therapies or as combination products exposes the company to additional risks and regulatory complexities.
• Inability to establish additional collaborations on commercially reasonable terms could alter development and commercialization plans.
• Regulatory authorities may not accept data from trials conducted outside their jurisdiction, requiring additional trials.
• Promotion of off-label uses is prohibited, and improper promotion could lead to significant liability.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties.
• Lack of prior experience commercializing anti-infective pharmaceuticals may hinder successful commercialization.
• Product candidates may face unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.
• Significant product liability risk exists, and insufficient insurance coverage could adversely affect the business.
• Inability to protect intellectual property (patents, trade secrets) or intellectual property disputes could result in loss of rights, need for third-party licenses, or reputational harm.
• Patent terms may not provide sufficient protection, and failure to obtain patent term extensions could harm the competitive position.
• Future issuances of preferred stock or additional common stock could dilute stockholders and lower the stock price.
• Increased costs and management time will be incurred as a public company, with potential for inadequate systems and resources for financial reporting.
• Internal computer systems or those of third parties may fail or experience security/data privacy breaches, leading to increased costs, revenue loss, and liabilities.
• Operations are vulnerable to disruptions from uncontrollable events like natural disasters or power outages.
• The company's independent registered public accounting firm's report contains an explanatory paragraph expressing substantial doubt about its ability to continue as a going concern.

Future Outlook

The company anticipates operating expenses will increase substantially as it advances its lead candidate Nu-3 through clinical trials, progresses additional pipeline candidates, expands discovery research, seeks regulatory approvals, and builds commercial infrastructure. It expects to continue incurring significant losses and negative cash flows for the foreseeable future until product sales generate revenue. The company plans to finance operations through equity offerings, debt financings, and licensing arrangements, but cannot assure that additional financing will be available on acceptable terms or at all.

Management Comments

• Management's plan to address the going concern uncertainty includes raising additional capital beyond the proceeds from this offering.
• Management believes the Bisphosphocin class of compounds is suitable for the treatment of a range of indications, including infected diabetic foot ulcer, urinary tract infections, and pulmonary infections.
• Management believes that Nu-3 gel, if confirmed clinically and approved, could become a competitive and relevant component in the care of infected diabetic foot ulcers, eliminating the need to wait for microbiological sampling and test results.
• Management believes that the methodologies used to determine the estimated fair value of our common stock are consistent with the guidance prescribed by the Financial Accounting Standards Board under ASC 718 and are reasonable for financial reporting purposes.

Industry Context

StockSavvy.ai notes that the biotechnology industry, particularly in infectious diseases, faces a growing global health crisis due to antimicrobial resistance (AMR), responsible for 1.27 million deaths annually. The market is characterized by intense competition and a critical need for new antimicrobial therapies, especially those with novel mechanisms of action to overcome existing resistance. Most recent drug developments have occurred within established antibiotic classes, leaving them vulnerable to known resistance mechanisms. Lakewood-Amedex's Bisphosphocin class, with its novel membrane-destabilizing mechanism, aims to address this unmet need, positioning it uniquely against competitors like Recce 327 and Pravibismane, which also target diabetic foot ulcers but may have different mechanisms or less comprehensive public data.

Comparison to Industry Standards

• The Bisphosphocin class's novel mechanism of action, designed to destabilize bacterial membranes, differentiates it from most existing antimicrobial agents that focus on established classes vulnerable to known resistance mechanisms (e.g., target modification, direct metabolism, efflux pump action).
• In vitro experiments suggest the Bisphosphocin class maintains antimicrobial activity against resistant pathogens like MRSA, while control antibiotics like ciprofloxacin showed significant resistance development (e.g., >2,000-fold for E. coli, >600-fold for MRSA), indicating a potential advantage over standard therapies.
• The local application strategy for Nu-3 in iDFU aims to overcome poor perfusion issues in diabetic patients, a limitation for systemic oral antibiotics, which currently lack published data demonstrating additive benefit over proper wound care in mild iDFU.
• Compared to other topical agents in development for DFU (e.g., Recce 327, Pravibismane), Lakewood-Amedex emphasizes its novel mechanism and activity against biofilm, which is a major problem in chronic infections and often reduces the efficacy of traditional antibiotics.
• The company's extensive patent portfolio (68 issued, 36 pending) is a strong competitive asset, providing broad protection for its novel class of compounds, which is crucial in the highly competitive biopharmaceutical sector.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not presently a party to any litigation that would have a material adverse effect on its business, operating results, cash flows, or financial condition.

Related Party Transactions

• In February and March 2026, the company issued five unsecured promissory notes totaling $125,000, with one member of the Board of Directors (Doug Manion, M.D.) purchasing two notes for $50,000.
• In May 2025, the company issued $1.25 million in convertible promissory notes and modified $250,000 of existing short-term notes held by directors, resulting in $1.5 million in convertible notes outstanding. Participants included Doug Manion ($50,000), Leonard J. DeRoma ($5,000), Peter Ceccacci ($25,000), and former Board Member Charles F. Wright ($300,000).
• As of December 31, 2023, the company owed $200,000 in principal and $138,020 in accrued interest to Lindesfarne LLC, a related party (second largest stockholder, 80% owned by trusts for the founder's children, 20% by former CEO). These notes were converted into 56,307 common shares on June 28, 2024, and the accrued interest of $143,020 was forgiven, treated as a capital contribution.

Stakeholder Impact

• **Shareholders:** Potential for significant dilution from the conversion of Series C Preferred Stock, especially if the common stock price falls. High volatility expected due to direct listing process. Existing shareholders may sell shares, increasing supply and potentially depressing price. Lock-up agreements for certain shareholders will temporarily restrict sales.
• **Employees:** Stock-based compensation is a significant component of executive compensation. Workforce reductions in R&D in 2025 indicate potential impact on employee numbers. Promotions of key executives (CEO, CFO, CMO) in 2025 reflect internal growth and leadership stability.
• **Customers (future):** If product candidates are approved, patients with infectious diseases, particularly iDFU, CAUTI, and pulmonary infections, could benefit from novel antimicrobial treatments, especially against resistant strains.
• **Creditors:** The company's going concern warning and reliance on future financing indicate elevated risk for creditors. Unsecured promissory notes and convertible notes represent current debt obligations.

Next Steps

• Complete the direct listing on the Nasdaq Capital Market under the symbol LABT, contingent on SEC and Nasdaq approval.
• Close the $7.5 million Series C Preferred Shares financing.
• Initiate a smaller single-blinded Phase 2a study for Nu-3 gel (2%, 5%, and 10% concentrations, twice daily) to establish early proof of concept and dose response in iDFU patients.
• Proceed with a fully blinded, placebo-controlled Phase 2b study for Nu-3 in iDFU to determine optimal dose and administration regimen, following the Phase 2a study.
• File a resale registration statement for the common stock underlying the Series C Preferred Stock and the Advisory Shares within 10 days of Nasdaq listing.
• Advance preclinical programs for additional Bisphosphocin compounds (Nu-8, Nu-10, Nu-11) targeting complicated Urinary Tract Infections (cUTI) and pulmonary infections.
• Conduct further profiling of portfolio compounds, including applicable animal models, to allow for IND filings and initiation of Phase 1 pilot studies for cUTI and pulmonary indications.
• Perform a detailed commercial assessment for CAUTI and pulmonary indications once development reaches the accepted IND and clinical phase milestones.
• Remediate identified material weaknesses in internal controls over financial reporting.
• Appoint a third independent director to the audit committee within one year of listing to comply with Nasdaq rules.

Key Dates

Keywords

Biotechnology, Antimicrobial Resistance, Infectious Diseases, Diabetic Foot Ulcers, Direct Listing, Nasdaq, Nu-3, Bisphosphocin, Clinical Trials, Drug Development, SEC Filing, S-1/A, Biopharmaceutical, MRSA, VRE, Antibiotics, Capital Raise, Series C Preferred Stock, Intellectual Property